On Monday, Shares of The Coca-Cola Company (NYSE:KO), lost -0.05% to $40.94.
Analysts at BMO Capital upgraded the soda company to “outperform” from “market perform”. The firm also raised its price target on the stock to $48 from $44.
BMO said it anticipates earnings growth in 2016 to approach the soda maker’s long-term targets.
Analysts at the firm added that in 2017, they see benefits from Coca Cola’s cost savings program.
The Coca-Cola Company, a beverage company, manufactures and distributes various nonalcoholic beverages worldwide. The company primarily offers sparkling beverages and still beverages. Its sparkling beverages comprise nonalcoholic ready-to-drink beverages with carbonation, such as carbonated energy drinks, and carbonated waters and flavored waters.
Shares of Gilead Sciences Inc. (NASDAQ:GILD), inclined 1.61% to $114.08, during its last trading session.
Gilead Sciences, declared results from the Phase 3 clinical Study 119 of an investigational use of Zydelig® (idelalisib) in combination with ofatumumab in formerly-treated patients with chronic lymphocytic leukemia (CLL). In Study 119, there was a 73 percent reduction in the risk of disease progression or death in patients receiving Zydelig in combination with ofatumumab contrast to ofatumumab alone (hazard ratio (HR) = 0.27; 95 percent CI: 0.19, 0.39; p<0.0001). Detailed results will be presented recently during a poster session at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #7023).
“The data stated recently reinforce preceding results showing that idelalisib, here in combination with the anti-CD20 monoclonal antibody ofatumumab, not only significantly improved overall and lymph node response rates, but more importantly progression-free survival in patients with formerly treated CLL,” said Jeffrey A. Jones, MD, MPH, Associate Professor of Medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). “Importantly, these improvements were also observed in patients with genetic features typically associated with poor prognosis.”
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical nee in North America, South America, Europe, and the Asia-Pacific.
At the end of Monday’s trade, Shares of Visa Inc. (NYSE:V), gained 0.63% to $69.11.
Visa, declared its participation in the following investor conference in the month of June.
On Wednesday, June 10, Vasant Prabhu, Chief Financial Officer, will present at the William Blair Growth Stock Conference in Chicago. The discussion will start at 3:40 p.m. Eastern Time and last for about 30 minutes.
Visa Inc., a payments technology company, operates as a retail electronic payments network worldwide. The company facilitates commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Finally, American Express Company (NYSE:AXP), ended its last trade with -0.31% loss, and closed at $79.47.
American Express Co. President Ed Gilligan, who died last week on a return trip from Tokyo, suffered an embolism and subsequent heart attack, according to a person briefed on the matter, Bloomberg Reports.
Flight attendants on the corporate jet en route to New York May 29 performed cardiopulmonary resuscitation on Gilligan, 55, before the plane made an emergency landing in Green Bay, Wisconsin, said the person, who asked not to be identified discussing personal matters. Two other executives were on board.
Blood clots, also called deep-vein thrombosis, can be a serious risk for long-distance travelers, according to the U.S. Centers for Disease Control & Prevention’s website. The longer a traveler is immobile, the greater the risk of developing a clot. Bloomberg added.
American Express Company, together with its auxiliaries, provides charge and credit payment card products and travel-related services to consumers and businesses worldwide.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
